BACKGROUND: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010-11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). METHODS: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012-2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. RESULTS: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0-88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8-96.1) < 12 months to 85.1% (72.0-92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7-94.7) against fatal PCV13 IPD, 64.5% (43.7-77.6), 83.2% (73.7-89.3) and 85.1% (67.6-93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3-94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4-92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2-96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and -14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. CONCLUSIONS: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.

Academic Medical Centre National Reference Laboratory for Bacterial Meningitis Amsterdam the Netherlands

ACTIV Créteil France

Bacterial Respiratory Infection Service Scottish Microbiology Reference Laboratory Glasgow Royal Infirmary and MVLS University of Glasgow Glasgow Scotland UK

Epiconcept Paris France

Epiconcept Paris France; Antwerp university Antwerp Belgium

European Centre for Disease Prevention and Control Stockholm Sweden

General Directorate of Public Health Madrid Spain

Health Agency of Catalunya Barcelona Spain; CIBER Epidemiología y Salud Pública Madrid Spain

Health Protection Surveillance Centre Dublin Ireland

Hospital Sant Joan de Déu and International University of Catalunya Barcelona Spain; CIBER Epidemiología y Salud Pública Madrid Spain

National Institute for Health and Welfare Helsinki Finland

National Institute for Health and Welfare Helsinki Finland; Tampere University Tampere Finland

National Institute for Public Health and the Environment Bilthoven the Netherlands

National Institute of Public Health Prague Czech Republic

Norwegian Institute of Public Health Oslo Norway

Public Health England London United Kingdom

Public Health Institute of Navarra IdiSNA Pamplona Spain; CIBER Epidemiología y Salud Pública Madrid Spain

Public Health Scotland Glasgow Scotland UK

Santé publique France the National Public Health Institute Saint Maurice France

Statens Serum Institut Copenhagen Denmark

Temple Street Children's University Hospital Irish Pneumococcal Reference Laboratory Dublin Ireland

References provided by Crossref.org

Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis